elvanse adult hart hylki 30 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 30 mg
elvanse adult hart hylki 50 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 50 mg
elvanse adult hart hylki 70 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 70 mg
volidax hart hylki 30 mg
teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 30 mg
volidax hart hylki 50 mg
teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 50 mg
volidax hart hylki 70 mg
teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 70 mg
elvanse adult hart hylki 20 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 20 mg
elvanse adult hart hylki 40 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 40 mg
elvanse adult hart hylki 60 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 60 mg
xalkori
pfizer europe ma eeig - crizotinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.